Medicines and Healthcare products Regulatory Agency, London, UK. eanda@davidson2.plus.com
Methods in molecular biology (Clifton, N.J.) 2013This chapter outlines a regulator's personal approach to the assessment of reproductive toxicology data in the context of the assessment of the overall nonclinical data package for pharmaceutical agents. Using as a framework the International Conference on Harmonisation Common Technical Document headings, guidance is provided on the expectations of regulators for the presentation and discussion of the data by the applicant to facilitate the risk assessment process. Consideration is given to the use of reproductive toxicology data in the assessment process for both clinical trial applications (CTAs) and marketing authorization applications (MAAs). Suggestions for some guiding principles in drafting of the various product information documents (for example the Investigator's Brochure (IB) for CTAs and the Nonclinical Overview and Summary of Product Characteristics for MAAs) are included.
Elizabeth Davidson. Regulatory assessment of reproductive toxicology data. Methods in molecular biology (Clifton, N.J.). 2013;947:489-516
PMID: 23138923
View Full Text